Title |
A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia
|
---|---|
Published in |
Annals of General Psychiatry, June 2010
|
DOI | 10.1186/1744-859x-9-27 |
Pubmed ID | |
Authors |
Akihiro Shiina, Yukihiko Shirayama, Tomihisa Niitsu, Tasuku Hashimoto, Taisuke Yoshida, Tadashi Hasegawa, Tadashi Haraguchi, Nobuhisa Kanahara, Tetsuya Shiraishi, Mihisa Fujisaki, Goro Fukami, Michiko Nakazato, Masaomi Iyo, Kenji Hashimoto |
Abstract |
Cognitive deficits in schizophrenia are associated with psychosocial deficits that are primarily responsible for the poor long-term outcome of this disease. Auditory sensory gating P50 deficits are correlated with neuropsychological deficits in attention, one of the principal cognitive disturbances in schizophrenia. Our studies suggest that the alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist tropisetron might be a potential therapeutic drug for cognitive deficits in schizophrenia. Therefore, it is of particular interest to investigate the effects of tropisetron on the cognitive deficits in patients with schizophrenia. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 4% |
United Kingdom | 1 | 1% |
Colombia | 1 | 1% |
Unknown | 67 | 93% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 11 | 15% |
Researcher | 9 | 13% |
Student > Doctoral Student | 8 | 11% |
Student > Bachelor | 8 | 11% |
Professor > Associate Professor | 6 | 8% |
Other | 15 | 21% |
Unknown | 15 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 19 | 26% |
Psychology | 11 | 15% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
Neuroscience | 4 | 6% |
Nursing and Health Professions | 3 | 4% |
Other | 10 | 14% |
Unknown | 21 | 29% |